# A burden-to-funding audit for gallbladder cancer and a dedicated research call

Source: https://onco.cc/ideas/idea-gbc-burden-to-funding-audit-and-dedicated-call/  
OnCo record `idea-gbc-burden-to-funding-audit-and-dedicated-call` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gallbladder cancer has been called scantily understood in 2004 and understudied in 2025 by its own researchers. Counting the money spent on it against the deaths it causes, country by country, would make the gap visible and give funders a target.

## Summary

The disease is common in Chile, Bolivia, northern India and parts of East Asia and rare in the countries that fund most cancer research; it is treated mostly by surgeons and pooled with cholangiocarcinoma in trials, so it has neither an advocacy base nor a trial portfolio of its own. Successive reviews (Wistuba and Gazdar 2004; Roa 2022; Zhu 2025) describe it as understudied and list the same unmet needs: screening biomarkers, standardised pathology, separate trials. The EULAT Eradicate GBC consortium (EU Horizon 2020) shows what a dedicated call can build. An audit of research spend against disability-adjusted life years, published and repeated, is the cheapest lever, followed by a targeted call from a funder with reach into both high-incidence and high-capacity countries.

## Fields

- Kind: Idea
- Last checked: 2026-09-24
- Tags: gallbladder-evidence
- Hypothesis: Publishing an annual burden-to-funding ratio for gallbladder cancer alongside other gastrointestinal cancers, and pairing it with a dedicated multi-country call, will at least double registered interventional trials naming gallbladder cancer as a primary population within five years.
- Rationale: Funding follows visibility; the disease's incidental diagnosis and trial pooling have kept it invisible in exactly the systems that allocate research money.
- Proposed test: Baseline audit using funder databases (NIH RePORTER, UKRI Gateway, Horizon Europe, CRUK) against GLOBOCAN burden; count of interventional trials with gallbladder cancer as primary population on ClinicalTrials.gov before and after a targeted call.
- Maturity: speculative
- Actor: philanthropy

## Sources

- Wistuba and Gazdar: gallbladder cancer, lessons from a rare tumour (Nat Rev Cancer 2004): https://europepmc.org/article/MED/15343276
- Scherer et al.: EULAT Eradicate GBC, the European-Latin American research consortium (Int J Epidemiol 2025): https://europepmc.org/article/MED/40735836

## Connected records

- collections: [GLOBOCAN / Global Cancer Observatory](https://onco.cc/collections/globocan/)
- cancers: [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- institutions: [Cancer Research UK](https://onco.cc/institutions/cruk/), [International Agency for Research on Cancer (IARC / WHO)](https://onco.cc/institutions/iarc/), [National Cancer Institute (NIH)](https://onco.cc/institutions/nci/)
- bottlenecks: [Funding follows fashion, not burden](https://onco.cc/bottlenecks/b-funding-allocation/), [Incentives reward me-too drugs and marginal gains](https://onco.cc/bottlenecks/b-incentive-misalignment/), [Rare and paediatric cancers without markets](https://onco.cc/bottlenecks/b-rare-cancers/)
- key papers: [Gallbladder cancer](https://onco.cc/key-papers/paper-roa-gallbladder-cancer-primer-nat-rev-dis-primers-2022/), [Gallbladder cancer: lessons from a rare tumour](https://onco.cc/key-papers/paper-wistuba-gazdar-gallbladder-cancer-lessons-nat-rev-cancer-2004/), [Population-Specific Immunogenomic Alterations in Gallbladder Cancer and Prognostic Significance](https://onco.cc/key-papers/paper-zhu-population-specific-immunogenomics-gallbladder-cancer-mod-pathol-2025/)
- roadmaps: [Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials](https://onco.cc/roadmaps/gallbladder-cancer-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-gbc-burden-to-funding-audit-and-dedicated-call.json